Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CTSV | O60911 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368594 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL5804644 | 0.94 | ALDH1A1 (0.57) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL750245 | 0.89 | CTSV (0.63) | ABCB1MAPTMEN1KMT2ACTSV | |
| SCHEMBL21775128 | 0.87 | SMN1; SMN2 (0.65) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL751415 | 0.87 | KMT2A (0.62) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL750963 | 0.87 | CTSV (0.58) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL9658186 | 0.87 | CTSV (0.58) | ALDH1A1LMNAABCB1MAPTMEN1 | |
| SCHEMBL16004968 | 0.87 | ABCB1 (0.59) | LMNAABCB1MAPTMEN1KMT2A | |
| SCHEMBL16004812 | 0.86 | MEN1 (0.64) | ALDH1A1ABCB1MAPTMEN1KMT2A | |
| SCHEMBL16005056 | 0.86 | ABCB1 (0.58) | ALDH1A1LMNAABCB1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-103664677-A | Asymmetric synthesis method of (R,R)-formoterol tartrate | UNIV SUN YAT SEN | 2014-03-26 | — | — | CN | claimed |
| CN-101468954-A | Unsymmetrical hydrogen migration synthesizing method for (R, R)-formoterol | UNIV ZHONGSHAN (CN) | 2009-07-01 | — | — | CN | claimed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| EP-0772585-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996004233-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-4473566-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-25 | — | — | US | disclosed |
| US-4254117-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4143166-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-03-06 | — | — | US | disclosed |
| US-4024281-A | N,N-bis[2-(3-substituted-4-hydroxyphenyl)-ethyl or -2-hydroxyethyl]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
| US-3933913-A | N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | ALDH1A1 802/4885LMNA 1446/4885ABCB1 452/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | ALDH1A1 4807/4885LMNA 4294/4885ABCB1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.